NEWSROOM
News & Stories
Newsroom
Press Releases
MammaPrint® Reimbursement Indication Extended in Belgium
IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS – February 11, 2025 – Agendia®, Inc. announced today that the National Institute for Sickness and Invalidity Insurance (INAMI-RIZIV) located in Brussels has expanded the reimbursement indication for Read More
Agendia Provides Review of Successful 2024 Advancing the Field of Breast Cancer Treatment
Year-to-Date Achievements Demonstrate Significant Signs of Growth Across All Sectors of Business IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS – January 9, 2025 – Agendia®, Inc. today provided a topline review of the company’s key Read More
Agendia Unveils New Real-World-Evidence from FLEX, Highlighting the Expanding Utility of MammaPrint and BluePrint for Predicting Neoadjuvant Chemosensitivity and Potential Resistance to CDK4/6 Inhibition in Early-Stage Breast Cancer at SABCS 2024
Gene expression analysis reveals MammaPrint® as the only commercially available genomic signature that may identify patient subgroups with resistance to CDK4/6 inhibition New real world evidence from FLEX adds to the growing body of Read More
Newsroom
News, Stories & Breast Cancer Blog
Improving Tailored Treatment Plans in HR+ and HER2- Early Breast Cancer
Genomic profiling in the FLEX trial predicted chemotherapy response in HR+, HER2- breast cancer, which could enable tailored treatment plans. In an abstract presented at the 2024 San Antonio Breast Cancer Symposium, researchers used genomic profiling in Read More
Healthcare Tech Outlook Named Agendia as One of the Top 10 Precision Oncology Solutions Providers in 2024
We are happy to announce Agendia has been named one of the Top 10 Precision Oncology Solutions Providers in 2024. Agendia is proud to be a part of the precision medicine movement with our Read More
What Is Neoadjuvant Chemotherapy?
If you or a loved one has been diagnosed with cancer, your care team may recommend chemotherapy, one of the most common types of cancer treatment available. Chemotherapy involves the use of medications that Read More
What Can We Learn From A Highly Diverse Observational Study Of 17,000+ Breast Cancer Patients?
A conversation with Agendia CMO William Audeh, MD More than 17,000 patients have enrolled in Agendia’s FLEX trial studying full genome profiling and complete clinical data for those diagnosed with stages I, II, or Read More
How Agendia is personalizing breast cancer treatment
By Abbey Bowling | October 29, 2024 October is Breast Cancer Awareness Month, and Agendia, one of the leading providers in the field of precision oncology is working to make a significant impact in Read More
How a Pregnant Woman Diagnosed With Breast Cancer Was Helped by MammaPrint
Aleseia Saunders was 32 when she felt a lump in her right breast. Being so young with no family history of breast cancer, she shrugged it off as being a cyst and went on Read More
Laura J. van ’t Veer, PhD, Honored With 2024 William L. McGuire Memorial Lecture Award at SABCS 2024
SAN ANTONIO – Laura J. van ’t Veer, PhD, will receive the William L. McGuire Memorial Lecture Award during the San Antonio Breast Cancer Symposium (SABCS) 2024, to be held December 10-13 at the Read More
